Quest AD-Detect Blood Test for Alzheimer's Disease

This trial examines whether a new blood test, called Quest AD-Detect, can help doctors diagnose Alzheimer's disease earlier in hospitalized patients with cognitive issues, such as confusion or memory problems. The goal is to determine if this test can distinguish between Alzheimer's and other causes of these issues. Participants will have a follow-up six months after leaving the hospital to discuss their results. Suitable candidates are those aged 60 to 90, currently hospitalized with cognitive problems, and without a prior dementia diagnosis. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could enhance early diagnosis of Alzheimer's disease.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Quest AD-Detect blood test can accurately identify Alzheimer's disease, with over 90% accuracy in both detecting the disease and confirming its absence. The test assesses the risk of dementia, including Alzheimer's, without involving medication, eliminating concerns about drug side effects. However, like any test, there is a small chance of a false positive or false negative result. Overall, the test is considered safe and easy to use.¹²³⁴⁵

The Quest AD-Detect blood test is unique because it offers a non-invasive way to detect Alzheimer's disease compared to traditional methods like brain imaging and spinal taps, which can be uncomfortable and costly. Researchers are excited about this test because it aims to identify Alzheimer's earlier by detecting specific biomarkers in the blood, potentially allowing for earlier intervention and better management of the disease. This could revolutionize how Alzheimer's is diagnosed, making it more accessible and less burdensome for patients.

Research has shown that the Quest AD-Detect blood test, provided to all eligible participants in this trial, accurately diagnoses Alzheimer's disease. Studies have found it correctly identifies Alzheimer's in 91% of cases and accurately rules it out in 91% of people without the disease. The test detects specific proteins in the blood, called amyloid-beta, linked to Alzheimer's. By tracking changes in these proteins, the test helps assess the risk of developing the disease. These findings suggest that the Quest AD-Detect blood test effectively distinguishes Alzheimer's from other memory and thinking problems.⁴⁵⁶⁷⁸